Polygenic Embryo Screening: Where Do We Stand? – ESHRE
European Society of Human Reproduction and Embryology (ESHRE) shared a post on LinkedIn:
“Polygenic Embryo Screening: Where Do We Stand?
Polygenic embryo screening (PES) can now assess IVF embryos for risks of heart disease, diabetes, schizophrenia and cancers. It’s already available, but highly controversial.
The disconnect: patients show strong interest – healthcare professionals have serious concerns.
Join this ESHRE webinar as international experts share new research on these diverging attitudes. Through focused presentations and panel discussion, we’ll explore:
- What drives patient demand vs. professional hesitation
- How views differ across cultures and demographics
- The implications for policy, education and patient care
Be part of shaping how we navigate this emerging frontier in hashtag#ReproductiveGenetics.
Date: 10 February 2026 | 17:00 CET
Find out more.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Jan 12, 2026, 16:03New Insights Into Estrogen Receptor Alpha Regulation in the Endometrium – Fertility and Sterility
-
Jan 12, 2026, 15:37From Innovation to Practice: Standards for Embryo Diagnostic Trials – Fertility and Sterility
-
Jan 12, 2026, 14:47HFEA Updates Choose a Fertility Clinic Tool to Improve Success Reporting
-
Jan 12, 2026, 13:14Lucile Ferreux: Prenatal Cadmium Exposure and Its Long-Term Impact on Male Fertility
-
Jan 12, 2026, 13:11This Month’s Fertility and Sterility Unplugged Is Live – Fertility and Sterility
-
Jan 11, 2026, 10:02Hind Hanani: Understanding the Use of Antiphospholipid Syndrome Guidelines Worldwide
-
Jan 11, 2026, 09:58Exploring the Role of Antiphospholipid Antibodies in Severe Preeclampsia – RheumNow
-
Jan 11, 2026, 09:56Adrenal Involvement in Antiphospholipid Syndrome – ARP Rheumatology
-
Jan 11, 2026, 09:52Jamie Agunsday: Understanding Pregnancy-Related Deaths